Remdesivir, convalescent plasma use based on limited available evidence: Health ministry

PTI, Jun 14, 2020, 8:05 PM IST

New Delhi: A day after allowing the use of antiviral drug remdesivir and off-label application of tocilizumab and convalescent plasma in moderate cases of COVID-19, the Union health ministry on Sunday said the “use of these therapies is based on limited available evidence at present”.

The ministry clarified that remdesivir has been included as an “investigational therapy” only for the purpose of restricted emergency use following certain news reports regarding the use of the drug as part of the clinical management protocols for COVID-19 and its availability in the country.

Restricted emergency use of drugs in the country for treatment of suspected or laboratory confirmed COVID-19 in adults and children hospitalised with severe disease is subject to a set of conditions.

Written informed consent of each patient is required before the use while results of additional clinical trials, active surveillance data of all treated patients, risk management plan along with active post-marketing surveillance and reporting of serious adverse events have to be submitted.

“Additionally, first three batches of imported consignments are to be tested and reports submitted to Central Drug Standard Control Organisation (CDSCO),” the ministry said.

Use of remdesivir under emergency use authorisation may be considered in patients at moderate stage of the disease, that is those on oxygen support, but with no specified contraindications, according to the health ministry’s revised ‘Clinical Management Protocols for COVID-19’ issued on Saturday.

On Sunday, the ministry said the drug has still not been approved (market authorization) by the US Food and Drug Administration (USFDA), where like India it continues only under emergency use authorization.

The ministry said Gilead Sciences had on May 29 applied to the Indian Drug Regulatory Agency, CDSCO, seeking nod for import and marketing of remdesivir.

After due deliberations, permission under emergency use authorization was granted on June 1 in the interest of patient safety and obtaining further data.

According to the statement six Indian companies– Hetero, Cipla, BDR, Jubilant, Mylan and DR Reddy’s Labs have also applied to CDSCO for permission to manufacture and market the drug in India.

Five of these have entered into an agreement with Gilead Sciences.

“These applications are being processed by the CDSCO on priority and in accordance with the laid down procedures.The companies are at various intermediate stages of inspection of manufacturing facilities, verification of data, stability testing, emergency laboratory testing as per protocol etc,” the statement said.

Being an injectable formulation, testing for assay, identity, impurities, bacterial endotoxin test and sterility become very critical for patient safety and this data need to be provided by the companies.

The CDSCO is awaiting the data and is providing complete support to these companies. It has already waived off the requirement of local clinical trials for these companies by invoking emergency provisions.

The regulatory processes are being facilitated and expedited by CDSCO, it said.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

SRH keep slim playoff hopes alive with three-run win over MI

Indian-American boy bullied at Texas school, then suspended for 3 days

Grappler Satender Malik gets life ban for assaulting referee during CWG 2022 wrestling trials

Clash during Irani’s program in Pune: case filed against BJP workers, party cries foul

Haridwar Dharma Sansad case: SC grants three months interim bail to hate speech accused

Ullal: Roof of dilapidated school building collapses; Major tragedy averted

K’taka Home Minister warns stringent action against those challenging law and order

Related Articles More

Biological E. cuts price of its COVID-19 vaccine to Rs 250 per dose

Active COVID-19 cases dip to 17,317

North Korea reports 8 deaths as Kim laments virus response

Karnataka records 126 new COVID-19 cases, zero fatalities

Facemasks can reduce Covid severity, pressure on health systems, study confirms


Boulder Collapse near Karinjeshwara Temple

Raghunath Rao Malkapure appointed pro tem chairman of Legislative Council

BJP members road Blocked in Chikkamagalur

NEWS BULLETIN 16-05-2022

Bajarangadal, called protest at Dattapeeta

Latest Additions

Moodabidri: Man killed in accident while returning home after employer’s funeral

Udupi: Woman goes missing with her 4-year-old daughter

UK lays out plans for new legislation to tackle post-Brexit Irish protocol

SRH keep slim playoff hopes alive with three-run win over MI

Indian-American boy bullied at Texas school, then suspended for 3 days

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.